Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Outset Medical (OM)
Express News | Gilead : RBC Raises Target Price to $84 From $83
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
8 Health Care Stocks Whale Activity In Today's Session
Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others
Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?
"Seladelpar Approved To Treat Adult Patients In The UK With Liver Illness; As With Any Medicine, The MHRA Will Keep The Safety And Effectiveness Of Seladelpar Under Close Review" - UK Gov
Express News | UK's Mhra: Seladelpar Approved to Treat Adult Patients in UK With Liver Illness - Website
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $115
Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $113
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)
Gilead Sciences reached a settlement with the USA government on a $1 billion patent dispute regarding AIDS drugs.
Gelonghui, January 16 | According to Reuters, a document submitted to the federal court in Delaware on Wednesday indicates that Gilead Sciences has reached a $1 billion settlement with the USA government regarding Gilead's HIV prevention drugs Truvada and Descovy. Previously, Gilead won a patent infringement lawsuit during a jury trial in 2023. Gilead's General Counsel Deborah Telman stated in a statement that the agreement allows "the company to continue focusing its resources on its mission to discover, develop, and provide innovative therapies to people with life-threatening diseases."
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Gilead Sciences, Inc. UK Regulatory Announcement: Form 8.3 - HOOKIPA Pharma Inc.
Express News | Gilead Exec Says Co Expects to Do "Something Like a CymaBay Acquisition Every Couple of Years" - JPM Healthcare Conf
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating